A controlled evaluation of ibuprofen and diazepam for chronic orofacial muscle pain

Journal of Orofacial Pain

Volumn 11, Issue 2, 1997, Pages 139-146

  Singer, Elyse ^a,b   Dionne, Raymond ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

endorphin; Chronic orofacial pain; Diazepam; Ibuprofen

Indexed keywords

ANXIOLYTIC AGENT; BETA ENDORPHIN; DIAZEPAM; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; EVALUATION; FACE PAIN; FEMALE; HUMAN; MALE; MYOFASCIAL PAIN; NONPARAMETRIC TEST; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; ANTI-ANXIETY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA-ENDORPHIN; DIAZEPAM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EVALUATION STUDIES; FACIAL PAIN; FEMALE; HUMANS; IBUPROFEN; MALE; PAIN MEASUREMENT; STATISTICS, NONPARAMETRIC; TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME;

EID: 0031082530     PISSN: 10646655     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Hargreaves AS, Wardle JJM. The use of physiotherapy in the treatment of temporomandibular disorders. Br Dent J 1983;155:121-124.
2. Jagger RG. Diazepam in the treatment of temporomandibular joint dysfunction syndrome - A double blind study. J Dent 1974;2:37-40.
3. Jagger RG. Pharmacotherapy of masticatory system dysfunction. J Prosthet Dent 1978;40:183-185.
4. Okeson JP, Moody DM, Kemper JT, Haley JV. Evaluation of occlusal splint therapy and relaxation procedures in patients with temporomandibular disorders. J Am Dent Assoc 1983;107:420-424.
5. Ramfjord SP, Ash MM. Occlusion. Philadelphia: Saunders, 1971:115-124.
6. Schwartz LL, Taussig DP. Temporomandibular joint pain-treatment with intramuscular infiltration of tetracaine hydrochloride: A preliminary report. NY State Dent J 1954;20:219-223.
7. Stenn PG, Mothersill KJ, Brooke RI. Biofeedback and a cognitive-behavioral approach to treatment of myofascial pain dysfunction syndrome. Behav Ther 1979;10:29-36.
8. Antczak-Bouckoms A. Reaction paper to chapter 12 and 13. In: Sessle BJ, Bryant PS, Dionne RA (eds). Temporomandibular Disorders and Related Pain. Seattle, IASP Press, 1995:237-245.
9. Fassbender HG. Pathology of Rheumatic Diseases. New York: Springer, 1975:303-314.
10. Goss AN, Speculand DB, Hallet E. Diagnosis of temporomandibular joint pain in patients seen at a pain clinic. J Oral Maxillofacial Surg 1985;43:110-114.
11. Greene CS. The fallacies of clinical success in dentistry. J Oral Med 1976;31:82-55.
12. Greene CS, Laskin DM. Splint therapy for the myofascial pain-dysfunction (MPD) syndrome: A comparative study. J Am Dent Assoc 1972;84:624-628.
13. Laskin DM, Greene CS. Influence of the doctor-patient relationship on placebo therapy for patients with myofascial pain-dysfunction (MPD) syndrome. J Am Dent Assoc 1972;85:892-894.
14. Goodman P, Greene CS, Laskin DM. Response of patients with myofascial pain-dysfunction syndrome to mock equilibration. J Am Dent Assoc 1976;92:755-758.
15. Laskin DM. Etiology of the pain-dysfunction syndrome. J Am Dent Assoc 1969;79:147-152.
16. Magnusson T, Egermark-Eriksson I, Carlsson GE. Five-year longitudinal study of signs and symptoms of mandibular dysfunction in adolescents. J Crainiomand Pract 1986;4:338-343.
17. Greene CS, Oleson RE, Laskin DM. Psychosocial factors in the etiology, progression, and treatment of MPD syndrome. J Am Dent Assoc 1983;105:443-448.
18. Moody PM, Kemper JT, Okeson JP, Calhoun TC, Parker MW. Recent life changes and myofascial pain syndromes. J Prosthet Dent 1982;48:328-330.
19. Schwartz RA, Greene CS, Laskin DM. Personality characteristics of patients with myofascial pain-dysfunction (MPD) syndrome unresponsive to conventional therapy. J Dent Res 1979;58:1435-1439.
20. Shipman WG, Greene CS, Laskin DM. Correlation of placebo response and personality characteristics in myofascial pain dysfunction (MPD) patients. J Psychosom Res 1974;18:475-483.
21. Speculand B, Goss AN, Spence ND, Pilowsky I. Intractable facial pain and illness behavior. Pain 1981;11:213-219.
22. Speculand B, Goss AN, Hughes A, Spence ND, Pilowsky I. Temporomandibular joint dysfunction: Pain and illness behavior. Pain 1983;17:139-150.
23. Greene CS, Laskin DM. Long-term evaluation of conservative treatment for myofascial pain-dysfunction syndrome. J Am Dent Assoc 1974;89:1365-1368.
24. Greene CS, Laskin DM. Long-term evaluation of treatment for myofascial pain-dysfunction syndrome: A comparative analysis. J Am Dent Assoc 1983;107:335-338.
25. Hargreaves KM, Dionne RA, Mueller G, Goldstein DS, Dubner R. Naloxone, fentanyl, and diazepam modify plasma beta-endorphin levels during surgery. Clin Pharmacol Ther 1986;41:165-171.
26. Troullos ES, Hargreaves KM, Goldstein DS, Stull R, Dionne RA. Epinephrine suppresses stress-induced increases in plasma immunoreactive beta-endorphin in humans. J Clin Endocrinol Metab 1989;69:546-551.
27. Hargreaves KM, Mueller G, Dubner R, Goldstein DS, Dionne RA. Corticotropin releasing factor (CRF) produces analgesia in humans and rats. Brain Res 1987;422:154-157.
28. Dionne RA, Troullos ES, Hargreaves KM. Ibuprofen elevates immunoreactive beta-endorphin in humans during surgical stress. Clin Pharmacol Ther 1997 (in press).
29. Hathaway SR, McKinley JC. Manual for the Minnesota Multiphasic Personality Inventory. New York: Psychological Corporation, 1967.
30. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
31. Scott J, Huskisson EC. Graphic representation of pain. Pain 1976;2:175-184.
32. Melzack R. The McGill Pain Questionnaire: Major properties and scoring methods. Pain 1975;1:277-299.
33. Spielberger CP, Gorsuch RL, Lushere RC. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, 1970.
34. McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service, 1971.
35. Lubin B, Levitt EE. Norms for the Depression Adjective Checklist: Age, group, and sex. J Consult Clin Psychol 1979;47:192.
36. Lubin B. Manual for the Depression Adjective Checklists. San Diego, CA: Educational and Industrial, 1981.
37. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70.
38. Bartels EM, Danneskoild-Samsoe B. Histological abnormalities in muscle from patients with certain types of fibrositis. Lancet 1986;1:755-757.
39. Fisher AA. Pressure algometry over normal muscles: Standard values, validity and reproducibility of pressure threshold. Pain 1987;30:115-126.
40. Kalyan-Raman UP, Kalyan-Raman K, Yunus MB, Masi AT. Muscle pathology in primary fibromyalgia: A light microscopic, histochemical, and ultrastructural study. J Rheumatol 1984;11:803-813.
41. Truelove EL. The chemotherapeutic management of chronic and persistent orofacial pain. Dent Clin North Am 1994;38:669-688.
42. Dworkin SF, Truelove EL, Bonica JJ, Sola A. Facial and head pain caused by myofascial and temporomandibular disorders. In: Bonica JJ (ed). The Management of Pain. Philadelphia, PA: Lea & Febiger, 1990:727-745.
43. American Academy of Orofacial Pain. McNeill C (ed). Temporomandibular Disorders. Guidelines for Classification, Assessment, and Management. Chicago: Quintessence, 1993:87.
44. Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E, Hautekeete ML. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: A case-control study. Gut 1991;32:730-734.
45. Laporte J-R, Carne X, Vidal X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet 1991;337:85-89.
46. Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm B-E, Alfredsson L, et al. Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993;53:485-494.
47. Gabriel SE, Jaakkimainen L, Bombardier C. Risk of serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs. Ann Intern Med 1991;115:787-796.
48. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: Effects on kidney function. J Clin Pharmacol 1991;31:588-598.
49. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and non-steroidal antiinflammatory drugs. N Engl J Med 1994;331:1675-1679.
50. Laskin DM. Myofascial pain-dysfunction syndrome etiology. In: Sarnat BG, Laskin DM (eds). The TMJ. A Biological Basis for Clinical Practice. Springfield, IL: Thomas, 1979:289-299.
51. Petersen FB, Christensen LV. Blood flow in human temporal muscle during tooth grinding and clenching as measured by 133 Xenon clearance. Scand J Dent Res 1973;81:272-275.
52. Onel Y, Friedman AP, Grossman J. Muscle blood flow studies in muscle-contraction headaches. Neurology 1961;11:935-939.
53. Gildenberg PL, DeVaul RA. The chronic pain patient: Evaluation and management. In: Gildenberg PL (ed). Pain and Headache, vol 7. New York: Karger, 1985.
54. Sammons EE. Drug use and misuse in chronic pain patients. Clin Anesth 1985;3:169-180.
55. Dellemijn PLI, Fields HL. Do benzodiazepines have a role in chronic pain management? Pain 1994;57:137-152.